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Introduction 
 
Many endocrinopathies are associated with impaired quality of life and psychiatric 
comorbidities. Personality changes are characteristic features of endocrine diseases 
and can even be the dominating symptom. In such circumstances, a patient will be 
treated for an apparent primary psychiatric condition whereas the underlying 
endocrine diagnosis is delayed for month or even years. It is textbook knowledge that 
mania and psychosis may be found in patients with severe hyperthyroidism, whereas 
patients with Cushing’s syndrome suffer frequently from depressive symptoms and 
cognitive disturbances. In pituitary diseases the spectrum depends on the underlying 
hyper- or hypofunction: Acromegalic patients have often maladaptive personality 
traits and higher rates of affective disorders, and patients with prolactinoma have 
changes in sleep pattern and cognition.  
 
Anxiety and depression in primary aldosteronism: often overlooked 
Primary aldosteronism affects - depending on hypertension prevalence in the 
respective target populations - 1 to 2 % of the general population (1). It comes with 
an increased risk of cardiovascular and renal comorbidities compared to 
hypertensives of similar age, sex and blood pressure. Contrary to other 
endocrinopathies psychiatric co-morbidities in patients with primary aldosteronism 
have only recently become a focus of attention.  
 
Several early case reports identified depression and anxiety disorders as symptoms 
associated with primary aldosteronism (2-5). It took until 2006 that Sonino et al. 
investigated 10 consecutive patients with primary aldosteronism using the Structured 
Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders (DSM-
IV) and the Diagnostic Criteria for Psychosomatic Research interview (6). As it tuned 
out, seven patients qualified for the diagnosis of a generalized anxiety disorder and 
one patient had an obsessive-compulsive disorder (Table 1). The patients also 
reported demoralization (n=5), persistent somatization (n=2) and irritable mood (n=1). 
In a controlled study, the same authors confirmed this finding in an independent 
cohort of 23 patients with primary aldosteronism in comparison to matched essential 
hypertensives and normotensive controls (7). Again, there was a striking prevalence 
of anxiety and to a lesser degree depression in the patients.  
 
In a large cross-sectional study we studied 132 patients with primary aldosteronism in 
different phases of the disease: at diagnosis before initiation of specific treatment, 4 
years after adrenalectomy, or 5 years after initiation of mineralocorticoid antagonist 
treatment (8). We assessed anxiety and depression by the validated questionnaires 
GAD-7 and PHQD. Compared to the normal German population patients with primary 
aldosteronism had higher prevalence rates for depression and anxiety, with females 
being more severely affected than males.  
 
Impaired quality of life in primary aldosteronism: is adrenalectomy better than 
mineralocorticoid antagonist treatment? 
The first study to investigate the longitudinal impact of adrenalectomy and 
mineralocorticoid antagonist treatment on quality of life was the Stowasser group 
from Australia. In their pilot study, quality of life was evaluated prospectively using the 
SF-36 questionnaire before and 3 and 6 months after unilateral adrenalectomy in 22 
patients  with primary aldosteronism (9). Pre-operatively, the patients had impaired 
quality of life in each quality of life domain compared to the Australian general 
population. Significant improvements were seen as early as 3 months after surgery, 
and to a similar degree 6 month after adrenalectomy. In a parallel protocol involving 
21 subjects with bilateral adrenal hyperplasia treated with spironolactone or amiloride 
quality of life at three month was again lower compared to adrenalectomized patients 
but normalized at 6 month (10). In summary, these studies suggested that the 
outcome of surgically and medically treated patients might be similar in terms of 
quality of life. However, limitations of both studies have been the relative short follow-
up and the limited number of subjects studied. Hence, whether long-term quality of 
life outcome of medical treatment is equivalent to adrenalectomy remained an open 
question. Since cardiovascular and renal outcomes seem to be similar between 
surgical and medical treatment (11) quality of life might become the only justification 
for surgery. 
In the study by Valema et al. published in this issue of JCEM the authors investigated 
quality of life in patients of the SPARTACUS trial (12). This was a randomized trial 
performed in 200 patients with primary aldosteronism in 12 Dutch centers and one 
Polish center. The primary objective of this trial was to compare the blood pressure 
outcome of computed tomography-based subtyping with that of adrenal vein 
sampling based subtyping. Surprisingly, blood pressure outcome (quantified as daily 
defined doses) was similar in both groups with a non-significant difference of 
remission rates. 92 patients were subjected to unilateral adrenalectomy, and 92 
patients to treatment with mineralocorticoid antagonist, and the authors used this 
cohort to analyze quality of life prospectively 6 and 12 month after start of therapy. 
Quality of life prior initiation of treatment was low in both groups, in line with the 
Stowasser group data, indicating a significant disease burden. Of note, female 
patients had worse scores than males. Quality of life improved substantially in both 
treatment arms although to a lesser degree in the MRA group. At last follow-up after 
12 month quality of life of the surgery group was equivalent or better that that of the 
normal population. In contrast, patients with bilateral adrenal hyperplasia treated with 
mineralocorticoid antagonists had improvements in quality of life without full recovery. 
More importantly, the surgery group had clinical meaningful higher scores than the 
mineralocorticoid antagonist group. In summary, based on quality of life this large 
prospective study is in favor of adrenalectomy. This could be a strong argument for 
screening and subtyping of primary aldosteronism: find the patient with unilateral 
aldosteronism, since long-term quality of life is better than putting the patient on 
mineralocorticoid antagonist therapy. That screening and subtyping of primary 
aldosteronism in general is a cost-effective, has been recently shown (13).  
 
Pathways by which aldosterone excess induce anxiety and depression and 
may impair quality of life 
 
Currently it remains an open question whether depression, anxiety and consecutively 
impaired quality of life are direct consequences of aldosterone excess via endocrine 
effects on the brain or result from uncontrolled hypertension. Evidence can be found 
for both concepts. The mineralocorticoid receptor function in the CNS has been 
implicated in the response to antidepressive treatment and in the mediation of anxiety 
related behavior. Moreover, the mineralocorticoid receptor seems also to be involved 
in emotional memory processes (as reviewed by Künzel (14)). A recent paradigm 
shift has been the implication of direct aldosterone actions at the level of 
mineralocorticoid receptors in the CNS. Formerly thought to be occupied by 
glucocorticoids in most parts of the brain, there is accumulating evidence that 
aldosterone acts selectively in relevant mood-regulating brain areas, without 
competing with cortisol/corticosterone (reviewed by (15)). In a rat model of 
depression subcutaneous aldosterone given via somotic minipumps induced an 
anhedonic state manifested by decreased sucrose preference, and a depression-like 
behavior in the forced swim test (16). On the other hand, besides direct aldosterone 
actions on the brain, uncontrolled or treatment resistant hypertension by itself could 
be a major factor causing anxiety and impaired quality of life (17). Patients with 
primary aldosteronism report of frequent visits to outpatient clinics for drug 
adjustments and unsuccessful attempts to reach blood pressure targets. They may 
have hypertensive emergencies, and suffer from insecurities resulting from high 
blood pressure readings when performing home blood pressure measurements. 
Resistant hypertension also could lead to cerebrovascular impairment and white 
matter lesions, in line with the ‘vascular hypothesis’ of depression (14).  
 
An alternative explanation comes from the steroid secretion patterns in primary 
aldosteronism. Using a mass spectrometry–based analysis of the 24-hour urine 
steroid metabolome in 174 patients with newly diagnosed primary aldosteronism we 
have recently reported significant cortisol co-secretion in the majority of patients (18). 
Quantitatively, the glucocorticoid excess was more pronounced than that found in so 
called subclinical Cushing’s syndrome (now termed autonomous cortisol secretion) 
but less than that typical for full-blown adrenal Cushing’s syndrome. Unilateral 
adrenalectomy abolished aldosterone excess and normalized glucocorticoid co-
secretion. Based on the simultaneous presence of   Cushing’s and Conn’s syndrome 
we termed this endocrine constellation Connshing’s syndrome. It is an attractive 
concept, that cortisol co-secretion might be detrimental for psychological well-being in 
untreated primary aldosteronism, and it could explain differences in quality of life in 
response to surgery or medical treatment. While adrenalectomy removes both 
mineralocorticoid and glucocorticoid excess, patients treated with mineralocorticoid 
receptor antagonist might have persistent and un-opposed glucocorticoid excess 
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Table 1: Prevalence of depression, anxiety and impaired quality of life in patients with 
primary aldosteronism 
Depression and Axiety 
 Author, year, 
questionnaire used 
Population Depression Anxiety disorder 
(6) Sonino, Fallo &Fava 
(2006); DSM-IV, DCPR 
 
10 patients with PA 10% 70% 
(7) Sonino et al. (2012); DSM-
IV, DCPR, PSI, SQ 
23 patients with PA  
versus 
23 patients with EH 
versus 











(8) Apostolopoulou et al.  
(2012); PHQD, GA/7 
27 patients with florid PA 
56 with chronic MRA therapy 
49 after adrenalectomy (4.3 years later) 










Quality of Life 
 Author, publication year, 
questionnaire used 
Population and intervention QoL at time of 
diagnosis 
QoL at follow-up 




QoL scores reduced 
compared to general 
population  for 
physical functioning, 
role physical, vitality, 
and general health  
QoL improved at 6 
month for physical 
functioning, role 
physical, general 
health, role emotional, 
mental health, and 
vitality 




QoL scores reduced 












health, vitality  
(11) Velema et al. (2017); SF-
36 










and mental QoL 




and mental QoL 
summary compared 
to normal population 
Normalized  QoL 





compared to unilateral 
PA physical and 
mental QoL lower 
 
 
PA= Primary aldosteronism; MRA = mineralocorticoid receptor antagonist treatment; n.a.= not available; PHQD= brief patient 
health questionnaire ; GAD-7 general anxiety disorder questionnaire; the Structured Clinical Interview for Diagnostic and 
Statistical Manual of Mental Disorders (DSM-IV); Diagnostic Criteria for Psychosomatic Research (DCPR); Psychosocial Index 
(PSI); the Symptom Questionnaire (SQ); SF-36 = Medical Outcomes Study Short Form 36 General Health Survey; EQ-5D = 
European Quality of Life-5 Dimensions instrument. 
 
 
